Products - Children and young people | Topic

Showing 21 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
Product type:
Guidance
Programme:
NICE guideline
Published:
27 November 2024
Maternal and child nutrition
Status:
In development
Programme:
NICE guideline
Expected publication date:
15 January 2025
Vamorolone for treating Duchenne muscular dystrophy [ID4024]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
22 January 2025
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 January 2025
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
24 April 2025
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in people 4 months and over ID6488
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years ID6510
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Digital support for children and young people with eating disorders:early value assessment
Status:
Awaiting development
Programme:
Health technology evaluation
Expected publication date:
TBC
Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years TS ID 12092
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Children and young people Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 21 products

Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)

Maternal and child nutrition

Vamorolone for treating Duchenne muscular dystrophy [ID4024]

Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]

Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment

Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]

Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]

Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806

Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]

Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]

Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

Vosoritide for treating achondroplasia in people 4 months and over ID6488

Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632

12 SQ-HDM SLIT for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites in children 5 to 11 years ID6510

Digital support for children and young people with eating disorders:early value assessment

Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years TS ID 12092

Children and young people Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 21 products

Product type
1 selected

New and updated
1 selected